Infectious complications of biologic treatments of rheumatoid arthritis.
about
Membrane TNF confers protection to acute mycobacterial infection.Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannanMembrane tumor necrosis factor confers partial protection to Listeria infection.Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection.Therapeutic potential of targeting IL-1 and IL-18 in inflammation.A review of rheumatoid arthritis affecting the foot and ankle.Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infectionCell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic sourceHost defenses against respiratory tract infection: implications for anti-inflammatory drug development and treatment.SD0006: a potent, selective and orally available inhibitor of p38 kinase.Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate.Regulation of TNF-α with a focus on rheumatoid arthritis.Cost of arthritis: a systematic review of methodologies used for direct costs.A 6-year trend of the healthcare costs of arthritis in a population-based cohort of older women.Relative contribution of IL-1α, IL-1β and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG.Parapharyngeal abscess in a patient receiving etanercept.Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
P2860
Q25257300-FC43C0D6-245B-47B9-A105-79556130577DQ28235685-D268FB66-B0C5-49C3-AF1C-F959F69E17FEQ35094506-6654C800-C0B4-432E-A2DA-468F90944CDDQ35623978-F92853A0-C289-4526-9DD5-93DAF9D90FADQ35790840-0FCC7039-4DDD-4D6C-AAEA-7E789A948AACQ36023833-1EBA4BC4-EAA3-4277-8B6E-E2E76819271AQ36638353-760B6512-0EF1-49D5-9AD2-5E1223AA6450Q36710557-44E2808C-CC0A-4B84-9E4F-DC588337F5DAQ37030665-DCDD97E8-855D-4CF7-AC64-1019A346FF60Q37466941-25C5A7BB-9377-45BA-AB78-6537779C530FQ37624175-DB2AD83C-0E36-42C8-A846-FF0670E81998Q38102876-263E63BC-C55E-4B0A-8D5B-60DB54EDB8F0Q38652998-CCC527D9-9465-4961-9826-612920FE5AABQ38947437-CE9E66F3-B637-48EB-9FD7-67314694D578Q41659293-F92D5ABA-39C2-4538-85A8-C66049C48F4BQ43445519-CEB66B97-2851-4507-AEA3-78673C37AB6DQ46803679-1F23FFB9-5446-4887-BA21-8D885A6B909E
P2860
Infectious complications of biologic treatments of rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Infectious complications of biologic treatments of rheumatoid arthritis.
@ast
Infectious complications of biologic treatments of rheumatoid arthritis.
@en
type
label
Infectious complications of biologic treatments of rheumatoid arthritis.
@ast
Infectious complications of biologic treatments of rheumatoid arthritis.
@en
prefLabel
Infectious complications of biologic treatments of rheumatoid arthritis.
@ast
Infectious complications of biologic treatments of rheumatoid arthritis.
@en
P2093
P1476
Infectious complications of biologic treatments of rheumatoid arthritis.
@en
P2093
Aparna K Mohan
Jeffrey N Siegel
M Miles Braun
Timothy R Coté
P304
P356
10.1097/00002281-200305000-00002
P577
2003-05-01T00:00:00Z